BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Labenz C, Prochaska JH, Huber Y, Nagel M, Straub BK, Wild P, Galle PR, Schattenberg JM. Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low-Density Lipoprotein Cholesterol. Hepatol Commun 2019;3:1472-81. [PMID: 31701071 DOI: 10.1002/hep4.1428] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Yilmaz Y, Byrne CD, Musso G. A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. Expert Rev Gastroenterol Hepatol 2021;15:345-52. [PMID: 33270482 DOI: 10.1080/17474124.2021.1860019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
2 Mendes TC, Silva GRD, Silva AO, Schaedler MI, Guarnier LP, Palozi RAC, Signor CT, Bosco JDD, Auth PA, Amaral EC, Froelich DL, Soares AA, Lovato ECW, Ribeiro-Paes JT, Gasparotto Junior A, Lívero FADR. Hepato- and cardioprotective effects of Baccharis trimera (Less.) DC. against multiple risk factors for chronic noncommunicable diseases. An Acad Bras Cienc 2021;93:e20200899. [PMID: 34161513 DOI: 10.1590/0001-3765202120200899] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol Metab 2020;42:101092. [PMID: 33010471 DOI: 10.1016/j.molmet.2020.101092] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
4 Labenz C, Kostev K, Kaps L, Galle PR, Schattenberg JM. Incident Dementia in Elderly Patients with Nonalcoholic Fatty Liver Disease in Germany. Dig Dis Sci 2021;66:3179-85. [PMID: 33037968 DOI: 10.1007/s10620-020-06644-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Eslam M, Alvani R, Shiha G. Obeticholic acid: towards first approval for NASH. Lancet. 2019;394:2131-2133. [PMID: 31813639 DOI: 10.1016/s0140-6736(19)32963-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
6 Schattenberg JM. Emerging Pharmacological Treatment in Nonalcoholic Steatohepatitis. Visc Med 2020;36:411-6. [PMID: 33251276 DOI: 10.1159/000507231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Labenz C, Huber Y, Michel M, Nagel M, Galle PR, Kostev K, Schattenberg JM. Impact of NAFLD on the Incidence of Cardiovascular Diseases in a Primary Care Population in Germany. Dig Dis Sci 2020;65:2112-9. [DOI: 10.1007/s10620-019-05986-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
8 Niederseer D, Wernly B, Aigner E, Stickel F, Datz C. NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations. J Clin Med 2021;10:467. [PMID: 33530440 DOI: 10.3390/jcm10030467] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Nier A, Huber Y, Labenz C, Michel M, Bergheim I, Schattenberg JM. Adipokines and Endotoxemia Correlate with Hepatic Steatosis in Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients 2020;12:E699. [PMID: 32151020 DOI: 10.3390/nu12030699] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
10 Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism 2020;111S:154170. [PMID: 32006558 DOI: 10.1016/j.metabol.2020.154170] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 29.0] [Reference Citation Analysis]
11 Stahmeyer JT, Hemmerling M, Burger B, Eberhard S, Krauth C, Zeidler J, Herr A, Weseloh H, Rossol S. [Frequency of diagnosed non-alcololic fatty liver disease (NAFLD) in the German population - An analysis based on health insurance data]. Z Gastroenterol 2021;59:851-8. [PMID: 33757144 DOI: 10.1055/a-1402-1263] [Reference Citation Analysis]
12 Kaps L, Labenz C, Galle PR, Weinmann-Menke J, Kostev K, Schattenberg JM. Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease. United European Gastroenterol J 2020;8:942-8. [PMID: 32698692 DOI: 10.1177/2050640620944098] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
13 Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut 2021;69:1691-705. [DOI: 10.1136/gutjnl-2020-320622] [Cited by in Crossref: 53] [Cited by in F6Publishing: 59] [Article Influence: 26.5] [Reference Citation Analysis]
14 Bisaccia G, Ricci F, Mantini C, Tana C, Romani GL, Schiavone C, Gallina S. Nonalcoholic fatty liver disease and cardiovascular disease phenotypes. SAGE Open Med 2020;8:2050312120933804. [PMID: 32612827 DOI: 10.1177/2050312120933804] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Schattenberg JM, Anstee QM, Caussy C, Bugianesi E, Popovic B. Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review. Expert Rev Gastroenterol Hepatol 2021;:1-14. [PMID: 34493137 DOI: 10.1080/17474124.2021.1974295] [Reference Citation Analysis]
16 Labenz C, Huber Y, Michel M, Nagel M, Galle PR, Kostev K, Schattenberg JM. Nonalcoholic Fatty Liver Disease Increases the Risk of Anxiety and Depression. Hepatol Commun 2020;4:1293-301. [PMID: 32923833 DOI: 10.1002/hep4.1541] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]